Source briefingJuly 4, 2026Research & Public Health
Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Date of authorisation: 19/06/2026, Status: Authorised
Source digest: Human medicines European public assessment report (EPAR): Rexatilux, ranibizumab, Date of authorisation: 19/06/2026, Status: Authorised
FreedomWitness note: This is an automatically published source digest, not a copied full article. FreedomWitness links to the original source so readers can verify the full context.
Continue reading
Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
by Yan Ning Li, Kumar S. D. Kothapalli, Susan E. Carlson, Byron J. Gajewski, Emily A. DeFranco, J. Thomas Brenna Background Spontaneous early preterm…
Heart attack, stroke — and hip fractures
Endocrinologist discusses life-or-death stakes of weak bones and how to protect against devastating falls
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products
Draft guideline on the requirements for demonstrating therapeutic equivalence for nasal products